Learn More
CONTEXT Despite concerns about drug safety, current information on older adults' use of prescription and over-the-counter medications and dietary supplements is limited. OBJECTIVE To estimate the prevalence and patterns of medication use among older adults (including concurrent use), and potential major drug-drug interactions. DESIGN, SETTING, AND(More)
OBJECTIVES Because of several recent clinical and regulatory changes regarding attention deficit-hyperactivity disorder (ADHD) in the United States, we quantified changes in the diagnosis of ADHD and its pharmacologic treatment from 2000 through 2010. METHODS We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit(More)
OBJECTIVE Concerns have been raised that antidepressants may be overused. This study aimed to provide an estimate of antidepressant overuse in a more recent, nationally representative sample of adults and with a more contemporary set of antidepressants than has been covered in prior studies. METHODS The data set included adult (weighted N=23,026,608)(More)
OBJECTIVE The authors examined trends in the use of second-generation antipsychotics for treatment of bipolar disorder before and after the U.S. Food and Drug Administration's approval in 2000 of olanzapine for use in treating acute manic episodes of bipolar disorder. METHODS The IMS Health National Disease and Therapeutic Index was used to derive monthly(More)
JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact support@jstor.org. The University of(More)
We are grateful to Bennett Erickson and Addison Wood for expert help with data preparation and analysis, and to Laura Panattoni and session participants at the June, 2014 American Society of Heath Economics meetings for valuable comments on an earlier version of the paper. We also thank Moneil for insightful comments and suggestions. Responsibility for the(More)
BACKGROUND We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib's price is expected to drop 70% to 90%. We hypothesized that initiating treatment with generic imatinib in these patients(More)
OBJECTIVE This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices. METHODS Data obtained from the IMS Health National Disease and Therapeutic Index, a nationally representative(More)
  • 1